Novel Recombinant Parapoxvirus Vectors Induce Protective Humoral and Cellular Immunity against Lethal Herpesvirus Challenge Infection in Mice
Open Access
- 1 September 2003
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 77 (17) , 9312-9323
- https://doi.org/10.1128/jvi.77.17.9312-9323.2003
Abstract
Orf virus (ORFV;Parapoxvirus ovis) was used to develop a novel vector system for the generation of effective and safe live vaccines. Based on the attenuated ORFV strain D1701-V, recombinants were produced that express the glycoproteins gC (D1701-VrVgC) or gD (D1701-VrVgD) of the alphaherpesvirus of swine, pseudorabies virus (PRV). Expression of gC and gD was also demonstrated on the surface of recombinant virus-infected murine cells that do not produce infectious ORFV. Single or combined immunization with the ORFV recombinants protected different mouse strains of a host species nonpermissive for ORFV against a fulminant, lethal PRV challenge infection equal to immunization with PRV live vaccine. Most notably, even a single immunization with D1701-VrVgC was protective, whereas two applications of D1701-VrVgD were required for immune protection. The higher protective capacity of D1701-VrVgC correlated with the induction of a strong specific humoral immune response. This suggestion was supported by transfer experiments using sera from recombinant-immunized mice, which resulted in partial gC but not gD antibody-mediated protection of the naïve recipients. Remarkably, immunization of different immune-deficient mice demonstrated that the application of the PRV gC-expressing recombinant controlled the challenge infection in the absence of either CD4+or CD8+T cells, B cells, or an intact perforin pathway. In contrast, D1701-VrVgD-immunized mice lacking CD4+T cells exhibited reduced protection, whereas animals lacking CD8+T cells, B cells, or perforin resisted the challenge infection. The present study demonstrates the potential of these new vector vaccines to efficiently prime both protective humoral and cell-mediated immune mechanisms in a host species nonpermissive for the vector virus.Keywords
This publication has 66 references indexed in Scilit:
- Immunogenicity and Safety of Defective Vaccinia Virus Lister: Comparison with Modified Vaccinia Virus AnkaraJournal of Virology, 2002
- Modulation of Cellular Responses by Plasmid CD40L: CD40L Plasmid Vectors Enhance Antigen-Specific Helper T Cell Type 1 CD4+T Cell-Mediated Protective Immunity against Herpes Simplex Virus Type 2in VivoHuman Gene Therapy, 2001
- Vaccine-Induced Serum Immunoglobin Contributes to Protection from Herpes Simplex Virus Type 2 Genital Infection in the Presence of Immune T CellsJournal of Virology, 2001
- Identification of three distinct antigenic sites in parapoxvirusesArchiv für die gesamte Virusforschung, 1997
- Immunobiology of pseudorabies (Aujeszky's Disease)Veterinary Immunology and Immunopathology, 1996
- Similar Immune Response to Nonlethal Infection with Herpes Simplex Virus-1 in Sensitive (BALB/c) and Resistant (C57BL/6) Strains of MiceCellular Immunology, 1994
- Evaluation of a recombinant vaccinia virus containing pseudorabies (PR) virus glycoprotein genes gp50, gII, and gIII as a PR vaccine for pigsArchiv für die gesamte Virusforschung, 1994
- Identification of the pseudorabies virus glycoprotein gp50 as a major target of neutralizing antibodiesArchiv für die gesamte Virusforschung, 1988
- Interferon-γ and B Cell Stimulatory Factor-1 Reciprocally Regulate Ig Isotype ProductionScience, 1987
- Recombinant Vaccinia Virus: Immunization Against Multiple PathogensScience, 1985